Andrew Cook, MD | Authors

Andrew Cook, MD, Discussed Exciting Clinical Trials Utilizing DART and Treatment De-Escalation in HPV+ OSCC

November 07, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to talk about exciting trials in the head and neck space, including the phase 2 ORATER2 and phase 3 MC1675 trials.

Andrew Cook, MD, on On-Going Clinical Research Efforts in the Head and Neck Cancer Space

November 06, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss ongoing trials on treatment de-escalation and mitigating mucositis-related pain in head and neck cancer.

Andrew Cook, MD, on the Potential Role of Gabapentin in Head and Neck Cancer

November 05, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss the potential role of gabapentin in head and neck cancer despite garnering negative results in oropharynx cancer.

Andrew Cook, MD, Discussed Outcomes with Gabapentin vs Opioids to Prevent Treatment-Related Pain in Oropharyngeal Cancer

November 04, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to discuss outcomes with gabapentin compared with opioids for increasing quality of life and decreasing treatment-related pain in oropharyngeal cancer.

Andrew Cook, MD, Discussed the Rational for Using Gabapentin to Prevent CRT-Related Pain in Oropharyngeal Cancer

November 03, 2021

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to talk about using prophylactic gabapentin for those receiving chemoradiotherapy for oropharyngeal cancer.